| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2026 | $38.00 | Buy → Neutral | Compass Point |
8-K - Chiron Real Estate Inc. (0001533615) (Filer)
8-K - Chiron Real Estate Inc. (0001533615) (Filer)
8-K - Chiron Real Estate Inc. (0001533615) (Filer)
10-Q - Chiron Real Estate Inc. (0001533615) (Filer)
8-K - Chiron Real Estate Inc. (0001533615) (Filer)
DEFA14A - Chiron Real Estate Inc. (0001533615) (Filer)
DEF 14A - Chiron Real Estate Inc. (0001533615) (Filer)
SCHEDULE 13G/A - Chiron Real Estate Inc. (0001533615) (Subject)
424B5 - Chiron Real Estate Inc. (0001533615) (Filer)
424B5 - Chiron Real Estate Inc. (0001533615) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
3 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Compass Point downgraded Chiron Real Estate from Buy to Neutral and set a new price target of $38.00
Fastest customizable press release news feed in the world
–Inaugural Senior Housing Investments Position Company for Growth– Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), announced today that it has completed the previously announced acquisition of The Landing (the "Landing") and The Riviera (the "Riviera"), two premier senior living communities located in the Washington, DC MSA, from affiliates of Silverstone Senior Living ("Silverstone") for an aggregate purchase price of $249 million. "Crossing the finish line on this transaction represents a significant milestone for Chiron as we successfully enter the senior housing space," said Mark Decker, Jr., Chief Executive Officer of Chiron Real Estate Inc. "The Landing and Riviera
Seasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt's next chapter of revenue-driven growth. Aditxt, Inc. (NASDAQ:ADTX)("Aditxt" or the "Company"), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision on
Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced the appointment of Charles Fitzgerald to the Company's Board of Directors (the "Board"), effective as of May 20, 2026, and the declaration of the Company's second quarter 2026 preferred dividends. Mr. Fitzgerald will serve as a member of the Board's Compensation and Nominating and Corporate Governance Committees. Underscoring his strong alignment with shareholder interests, Mr. Fitzgerald holds 97,293 shares of Chiron common stock via affiliated entities, representing approximately $3.4 million of invested capital. Appointment of Charles Fitzgerald to the Board Mr. Fitzgerald, age 51, is the Founder and Ma
Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced the entry into an agreement providing for up to a $100 million delayed-draw convertible perpetual preferred equity investment led by Maewyn Capital Partners ("Maewyn"). "This growth equity investment represents an important milestone in the repositioning of Chiron. Maewyn's capital provides long-term flexibility and is expected to accelerate our transition toward higher-return opportunities across the healthcare real estate spectrum. We are focused on disciplined capital allocation and believe this investment further aligns our capital structure with our objective of driving long-term earnings growth," said Ma
–Inaugural Senior Housing Investments Marks Milestone in Company Growth Plan– –Luxury Communities Located in Premium Submarkets Targeting Affluent Residents– Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced that it has entered into purchase agreements relating to the acquisition of three seniors housing communities from affiliates of Silverstone Senior Living ("Silverstone") for an aggregate purchase price of $425 million. Silverstone will continue to play an active oversight role in the operations of the communities, and Greystone will continue to manage the properties. "These acquisitions represent Chiron's initial entry into seniors housing and advanc
–Announces Contracts for Three Seniors Housing Communities for an Aggregate Purchase Price of $425 Million– –Announces $100 Million Strategic Equity Investment from Maewyn Capital Partners– –Announces Reduction in Monthly Dividend to Facilitate New Strategic and Growth Plans– Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced financial results for the three months ended March 31, 2026 and other data. Mark Decker, Jr., Chief Executive Officer and President stated, "Chiron is repositioning as a growth-oriented investor. Central to this transition is a disciplined capital allocation strategy aimed at recycling capital into investments with higher returns on
Chiron Real Estate Inc. (NYSE:XRN) (the "Company"), announced today that it intends to release its first quarter 2026 financial results after the market closes on Wednesday, May 6, 2026. The Company intends to hold a conference call to discuss those results the following day, Thursday, May 7, 2026, at 9:00 a.m. Eastern Time. The conference call will be hosted by President and Chief Executive Officer Mark Decker, Jr., Chief Financial Officer Robert Kiernan, Chief Investment Officer Alfonzo Leon and Chief Operating Officer Danica Holley. Webcast Information Participants may access the call via live webcast by visiting the "Investor Relations" section of the Company's new website at www.ch
Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most
–Completes Corporate Rebrand– –Announces 2026 Strategic Objectives & Full Year 2026 Core FFO Guidance– –Announces Change from Quarterly to Monthly Dividends– Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced financial results for the three and twelve months ended December 31, 2025 and other data. Mark Decker, Jr., Chief Executive Officer and President stated, "We're about eight months into the transformation of the business and we are making great progress. I'm grateful for all the hard work that's produced these early results and the support of our Board. We can see the business we want and a path to get there. As this quarter demonstrates, we have a s
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
4 - Chiron Real Estate Inc. (0001533615) (Issuer)
Live finance-specific insights
Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced the entry into an agreement providing for up to a $100 million delayed-draw convertible perpetual preferred equity investment led by Maewyn Capital Partners ("Maewyn"). "This growth equity investment represents an important milestone in the repositioning of Chiron. Maewyn's capital provides long-term flexibility and is expected to accelerate our transition toward higher-return opportunities across the healthcare real estate spectrum. We are focused on disciplined capital allocation and believe this investment further aligns our capital structure with our objective of driving long-term earnings growth," said Ma
–Announces Contracts for Three Seniors Housing Communities for an Aggregate Purchase Price of $425 Million– –Announces $100 Million Strategic Equity Investment from Maewyn Capital Partners– –Announces Reduction in Monthly Dividend to Facilitate New Strategic and Growth Plans– Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced financial results for the three months ended March 31, 2026 and other data. Mark Decker, Jr., Chief Executive Officer and President stated, "Chiron is repositioning as a growth-oriented investor. Central to this transition is a disciplined capital allocation strategy aimed at recycling capital into investments with higher returns on
Chiron Real Estate Inc. (NYSE:XRN) (the "Company"), announced today that it intends to release its first quarter 2026 financial results after the market closes on Wednesday, May 6, 2026. The Company intends to hold a conference call to discuss those results the following day, Thursday, May 7, 2026, at 9:00 a.m. Eastern Time. The conference call will be hosted by President and Chief Executive Officer Mark Decker, Jr., Chief Financial Officer Robert Kiernan, Chief Investment Officer Alfonzo Leon and Chief Operating Officer Danica Holley. Webcast Information Participants may access the call via live webcast by visiting the "Investor Relations" section of the Company's new website at www.ch
Live Leadership Updates
Seasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital markets depth, healthcare sector expertise, and commercial discipline to lead Aditxt's next chapter of revenue-driven growth. Aditxt, Inc. (NASDAQ:ADTX)("Aditxt" or the "Company"), a life sciences platform company accelerating promising health innovations, today announced the appointment of Jeffrey M. Busch as Interim Chief Executive Officer of Aditxt, Inc., effective May 31, 2026. Mr. Busch, who has served as Chief Executive Officer of Aditxt's CLIA-certified precision on
Chiron Real Estate Inc. (NYSE:XRN) (the "Company" or "Chiron"), today announced the appointment of Charles Fitzgerald to the Company's Board of Directors (the "Board"), effective as of May 20, 2026, and the declaration of the Company's second quarter 2026 preferred dividends. Mr. Fitzgerald will serve as a member of the Board's Compensation and Nominating and Corporate Governance Committees. Underscoring his strong alignment with shareholder interests, Mr. Fitzgerald holds 97,293 shares of Chiron common stock via affiliated entities, representing approximately $3.4 million of invested capital. Appointment of Charles Fitzgerald to the Board Mr. Fitzgerald, age 51, is the Founder and Ma
Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein profiling. The platform measures active proteins inside tumors to help oncologists determine which targeted therapies are most